Delta biosciences - Company finances
|
EUR
|
2020
From: 2020-11-13
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|
|
Financial data
|
||||||
| Sales revenue | - | 3,100 | 12,700 | - | 79,979 | 102,449 |
| Profit before tax | -873 | -35,705 | 12,089 | -80,684 | 2,068 | 1,499 |
| Net profit | -873 | -35,705 | 11,538 | -80,684 | 1,970 | 1,406 |
| Equity | 4,127 | -31,579 | -20,041 | -100,725 | -98,755 | -97,349 |
| Liabilities | 2,916 | 219,823 | 45,791 | 125,952 | 179,414 | 166,437 |
| Non-current assets | 0 | 186,601 | 201,841 | 133,787 | 65,734 | 65,734 |
| Current assets | 4,843 | 70,742 | 3,149 | 18,398 | 14,925 | 3,354 |
| Total assets | 4,843 | 257,343 | 204,990 | 152,185 | 80,659 | 69,088 |
|
Taxes paid
|
||||||
| STI taxes | - | - | - | 8,429 | 14,014 | 17,390 |
| Social insurance contributions | - | - | - | 16,655 | 17,584 | 26,916 |
|
Financial indicators
|
||||||
| Revenue change y/y | - | - | +309.7% | - | - | +28.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -18.0% | -13.9% | 5.6% | -53.0% | 2.4% | 2.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -21.2% | - | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | -1151.8% | 90.9% | - | 2.5% | 1.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | -1151.8% | 95.2% | - | 2.6% | 1.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.7 | - | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 298 | 1,181 | - | 12,464 | 10,690 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Delta biosciences - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-17 | 2026-05-17 | 913.11 |
| 2026-03-27 | 2026-03-27 | 652.93 |
| 2026-03-17 | 2026-03-19 | 652.93 |
| 2025-03-18 | 2025-03-18 | 982.49 |
| 2024-08-19 | 2024-08-20 | 525.30 |
| 2023-10-17 | 2023-10-19 | 225.23 |
| 2023-09-18 | 2023-10-09 | 0.14 |
| 2023-08-17 | 2023-09-06 | 0.14 |
| 2023-07-24 | 2023-08-06 | 0.29 |
| 2023-05-02 | 2023-05-14 | 0.76 |
| 2023-04-27 | 2023-04-28 | 0.76 |
| 2023-04-25 | 2023-04-25 | 0.76 |
| 2023-04-18 | 2023-04-19 | 1304.36 |
| 2023-03-17 | 2023-03-22 | 3.26 |
| 2023-03-16 | 2023-03-16 | 1260.26 |
| 2023-02-17 | 2023-03-15 | 4.07 |
| 2023-02-06 | 2023-02-12 | 4.07 |
| 2023-01-17 | 2023-02-03 | 4.07 |
| 2022-12-16 | 2023-01-12 | 4.07 |
| 2022-11-21 | 2022-12-08 | 4.07 |
| 2022-11-17 | 2022-11-18 | 4.07 |
| 2022-10-31 | 2022-11-06 | 4.07 |
| 2022-07-25 | 2022-08-08 | 56.67 |
| 2022-06-16 | 2022-06-26 | 5469.29 |
| 2022-06-08 | 2022-06-15 | 0.66 |
| 2022-05-19 | 2022-05-26 | 4729.07 |
| 2022-05-17 | 2022-05-18 | 5433.07 |
| 2022-05-10 | 2022-05-16 | 703.28 |
| 2022-04-19 | 2022-05-09 | 5433.28 |
| 2022-01-28 | 2022-02-07 | 6.41 |
| 2021-10-18 | 2021-10-18 | 5342.19 |
Delta biosciences - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-07-03 | 2026-07-07 | 1050.29 |
| 2026-06-26 | 2026-07-02 | 284.36 |
| 2025-09-16 | 2025-10-18 | 3.73 |
| 2025-09-13 | 2025-09-15 | 10.2 |
| 2025-07-16 | 2025-07-20 | 762.98 |
| 2024-12-08 | 2024-12-08 | 103.33 |
| 2024-12-06 | 2024-12-07 | 103.53 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Delta biosciences, UAB (company code 305656641) is a private limited liability company engaged in research and experimental development on other natural sciences and engineering. In 2025, the company generated revenue of €102.4K, up 28.1% year on year, and recorded net profit of €1.4K, with a profit margin of 1.4%. This followed a 2024 result of €80.0K in revenue and €2.0K net profit, after a 2023 net loss of €80.7K. The three-year pattern shows a clear shift from loss to modest profitability, alongside continued sales growth. At the end of 2025, total assets stood at €69.1K, including €65.7K of long-term assets and €3.4K of short-term assets. Liabilities were €166.4K and equity remained negative at €97.3K, indicating a leveraged balance sheet structure. Asset turnover was 1.48x, and return on assets was 2.0%. Revenue per employee in 2025 was €11.4K, while profit per employee was €156.